References
- Benirschke K, Driscoll SG. The Pathology of the Human Placenta. Springer-Verlag, New York 1967
- Fox H. Pathology of the Placenta. Saunders, Philadelphia 1978
- Altshuler G, McAdams AJ. The role of the placenta in perinatal pathology. Am J Obstet Gynecol 1972; 113: 616–626
- Blanc WA. The future of antepartum morphologic studies. Diagnosis and Treatment of Fetal Disorders, K Adamsons. Springer-Verlag, New York 1969; 15–49
- Ornoy A, Crone K, Altshuler G. Pathological features of the placenta in fetal death. Arch Pathol Lab Med 1976; 100: 367
- Ornoy A, Salamon-Arnon J, Ben-Zur Z, Kohn G. Placental findings in spontaneous abortions and stillbirths. Teratology 1981; 24: 243–252
- Spellacy WN, Cohen WD, Carlson KL. Human placental lactogen levels as a measure of placental function. Am J Obstet Gynecol 1967; 97: 560–561
- Spellacy WN, Buhi WC, Birk SA. The effectiveness of human placental lactogen measurements as an adjunct in decreasing perinatal deaths. Results of a retrospective and a randomized controlled prospective study. Am J Obstet Gynecol 1975; 121: 835–844
- Stemberger LA, Hardy PH, Cuculis JJ, Meyer HG. The unlabeled antibody-enzyme method of immunohistochemistry. Preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes. J Histochem Cytochem 1970; 18: 315
- Immuno-cytochemistry2nd ed., LA Sternberger. Wiley and Sons, New York 1979
- Boenisch T. Reference Guide Series 1. Pap/immunoperoxidase. DAKO Corp., Santa Barbara 1980; 3–18
- Josimovich JB, MacLaren JA. Presence in the human placenta and term serum of a highly lactogenic substance immunologically related to pituitary growth hormone. Endocrinology 1966; 71: 209–220
- Grumbach MM, Kaplan SL. On placental origin and purification of chorionic “growth-hormone prolacting” and its immunoassay in pregnancy. Trans NY Acad Sci 1964; 27: 167–188
- Saxena BN, Emerson K, Selenkow HA. Serum placental lactogen (HPL) levels as an index of placenta function. N Engl J Med 1969; 281: 225–231
- Keller PJ, Bader P, Schmid J, Baertschi U, Gerber C, et al. Biochemical detection of fetoplacental distress in risk pregnancies. Lancet October 2, 1971; 729–731
- Letchworth AT, Chard T. Placental lactogen levels as a screening test for fetal distress and neonatal asphyxia. Lancet April 1, 1972; 704–706
- Lindberg BS, Nilsson BA. Human placental lactogen (HPL) levels in abnormal pregnancies. J Obstet Gynaecol Br Cmwlth 1973; 80: 1046–1053
- England P, Fergusson JC, Lorrimer D, Mofatt AM, Kelly AM. The human placental lactogen: The watchdog of fetal distress. Lancet January 5, 1974; 5–6
- Letchwroth AT, Slattery M, Dennis KJ. Clinical application of human-placental-lactogen values in late pregnancy. Lancet May 6, 1978; 955–957
- Curzen P. Prognostic value of fetoplacental function tests: A review. J R Soc Med 1979; 72: 118–122
- Garoff L, Seppala M. Toxemia of pregnancy: Assessment of fetal stress by urinary estriol and circulating human placental lactogen and alpha-fetoprotein levels. Am J Obstet Gynecol 1976; 126: 1027–1033
- Robinson JS. Placental lactogen. Abnormal Fetal Growth: Biological Bases and Consequences, F Naftolin. Abakon Verlagsgesellschaft, Berlin 1978; 49–68
- Heyderman E, Gibbons AR, Rosen SW. Immunoperoxidase localization of human placental lactogen: A marker for the placental origin of the giant cells in 'syncytial endometritis' of pregnancy. J Clin Pathol 1971; 34: 303–307